Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells

Thyroid

Volumn 22, Issue 2, 2012, Pages 138-144

  D'Agostino, Maria ^a   Voce, Pasquale ^b   Celano, Marilena ^a   Sponziello, Marialuisa ^c   Moretti, Sonia ^b   Maggisano, Valentina ^a   Verrienti, Antonella ^c   Durante, Cosimo ^c   Filetti, Sebastiano ^c   Puxeddu, Efisio ^b   Russo, Diego ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PROTEIN KINASE B; SUNITINIB; THYROGLOBULIN; THYROID PEROXIDASE; THYROTROPIN RECEPTOR; VASCULOTROPIN A;

APOPTOSIS; CANCER CELL CULTURE; CELL COUNT; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; DRUG EFFECT; DRUG EXPOSURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; WESTERN BLOTTING;

ANGIOGENESIS INDUCING AGENTS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; HUMANS; INDOLES; IODIDE PEROXIDASE; MAP KINASE SIGNALING SYSTEM; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PYRROLES; RECEPTORS, THYROTROPIN; SYMPORTERS; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 84856610762     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0060     Document Type: Review

References (34)

1. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlum-berger M 1999 Sodium/iodide symporter (NIS): a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 141:443-457.
2. Arturi F, Russo D, Giuffrida D, Schlumberger M, Filetti S 2000 Sodium-iodide symporter (NIS) gene expression in lymph node metastases of papillary thyroid carcinomas. Eur J Endocrinol 143:623-627.
3. Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM 2007 Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 3:263-269.
4. O'Neill CJ, Oucharek J, Learoyd D, Sidhu SB 2010 Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 15:146-156.
5. Smallridge RC, Marlow LA, Copland JA 2009 Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Rel Cancer 16:17-44.
6. Sherman SI 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin En-docrinol Metab 94:1493-1499.
7. Woyach JA, Shah MH 2009 New therapeutic advances in the management of progressive thyroid cancer. Endocr Rel Cancer 16:715-731.
8. Schlumberger M, Sherman SI 2009 Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 19:1393-1400.
9. Fagin JA 2004 How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183:249-256. (Pubitemid 39562707)
10. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG 2010 Phase II study of daily Sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16:5260-5268.
11. Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G, Rischin D 2008 Sustained clinical responses to tyrosine kinase inhibitor Sunitinib in thyroid carcinoma. Anticancer Drugs 19:547-552. (Pubitemid 351556406)
12. Cohen EEW, Needles BM, Cullen KJ, Wong S, Wade J, Ivy P, Villaflor V, Seiwert T, Nichols K, Vokes EE 2008 Phase 2 study of Sunitinib in refractory thyroid cancer. J Clin Oncol 26:6025.
13. Chow LQ, Eckhardt SG 2007 Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896. (Pubitemid 350002890)
14. Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cher-rington JM, Hu-Lowe D 2006 SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 5:1774-1782. (Pubitemid 44323245)
15. Fenton MS, Marion KM, Salem AK, Hogen R, Naeim F, Hershman JM 2010 Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Thyroid 20:965-974.
16. Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V, Parangi S 2009A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid 19:1077-1084.
17. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M 2006 An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076. (Pubitemid 44536887)
18. Schweppe RE, Klopper JP, Korch C, Puqazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331-4341. (Pubitemid 352789529)
19. Franzoni A, Dima M, D'Agostino M, Puppin C, Fabbro D, Di Loreto C, Pandolfi M, Puxeddu E, Moretti S, Celano M, Bruno R, Filetti S, Russo D, Damante G 2009 Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAFV600E mutation. Thyroid 19:247-255.
20. Gioanni J, Zanghellini E, Mazeau C, Zhang D, Courdi A, Farges M, Lambert JC, Duplay H, Schneider M 1991 Characterization of a human cell line from an anaplastic carcinoma of the thyroid gland. Bull Cancer 78:1053-1062.
21. Husmark J, Heldin NE, Nilsson M 1999 N-cadherin-mediated adhesion and aberrant catenin expression in anaplastic thyroid-carcinoma cell lines. Int J Cancer 83: 692-699. (Pubitemid 29508052)
22. Celano M, Schenone S, Cosco D, Navarra M, Puxeddu E, Racanicchi L, Brullo C, Varano E, Alcaro S, Ferretti E, Botta G, Filetti S, Fresta M, Botta M, Russo D 2008 Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr Rel Cancer 15:499-510. (Pubitemid 351880838)
23. Russo D, Bisca A, Celano M, Talamo F, Arturi F, Scipioni A, Presta I, Bulotta S, Ferretti E, Filetti S, Scaloni A, Damante G, Tell G 2005 Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells. J Endocrinol Invest 28:137-144. (Pubitemid 43162789)
24. Sponziello ML, Bruno R, Durante C, D'Agostino M, Corra-dino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, Filetti S, Russo D 2010 Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. Horm Metab Res 43:22-25.
25. Romagnoli S, Moretti S, Voce P, Puxeddu E 2009 Targeted molecular therapies in thyroid carcinoma. Arq Bras En-docrinol Metab 53:1061-1073.
26. Salem AK, Fenton MS, Marion KM, Hershman JM 2008 Effect of Sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 18:631-636.
27. Kaldrymides P, Kostoglou-Athanassiou I, Gkountouvas A, Veniou E, Ziras N 2010 Partial remission of metastatic papillary thyroid carcinoma with Sunitinib. Report of a case and review of the literature. Endocrine 37:6-10.
28. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Jusuff N, Batt D, Fagin JA 2006 Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12:1785-1793.
29. Makita N, Miyakawa M, Fujita T, Iiri T 2010 Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 20:323-326.
30. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plénat F, Leclère J, Duprez A, Weryha G 2001 Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86:656-658. (Pubitemid 32207476)
31. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL, Tuttle RM 2001 Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129:552-558. (Pubitemid 32374986)
32. Tuttle RM, Fleisher M, Francis GL, Robbins RJ 2002 Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 87:1737-1742. (Pubitemid 34615263)
33. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B 2007 Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 14:719-729. (Pubitemid 46175318)
34. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M 2006 Influence of the BRAF V600E mutation on expression of vascular endo-thelial growth factor in papillary thyroid cancer. J Clin En-docrinol Metab 91:3667-3670. (Pubitemid 44402153)